Here are 1-2 brief analogies to describe RadNet (RDNT):

• Quest Diagnostics for diagnostic imaging services: RadNet operates a large national network of outpatient diagnostic imaging centers (MRI, CT, X-ray, mammography), similar to how Quest Diagnostics operates a vast network of clinical laboratories.
• DaVita for radiology centers: Like DaVita manages a nationwide chain of specialized outpatient dialysis clinics, RadNet runs a widespread network of dedicated facilities for medical imaging scans.

• Outpatient Diagnostic Imaging Services: Provides a comprehensive suite of diagnostic imaging procedures, including MRI, CT, X-ray, ultrasound, mammography, and PET/CT, primarily in an outpatient setting.
• Interventional Radiology Services: Offers minimally invasive, image-guided procedures used to diagnose and treat diseases in nearly every organ system.
• AI-Powered Imaging and Teleradiology Solutions: Develops and deploys artificial intelligence solutions for image interpretation and provides teleradiology services, allowing for remote reading of medical images.
• Clinical Research Services: Conducts clinical trials and provides related research services for pharmaceutical and biotechnology companies.

RadNet (RDNT) operates a network of outpatient diagnostic imaging centers. While it directly serves millions of individual patients receiving diagnostic imaging services, a significant and growing portion of its strategic focus and revenue generation comes from partnerships and joint ventures with large healthcare systems and physician groups. In these arrangements, RadNet provides its operational expertise, technology, and management services, making these health systems major strategic customers or partners.

RadNet's business model involves substantial sales and services to other companies, primarily through joint ventures where it co-owns and manages imaging facilities with hospital systems. These partnerships effectively make the health systems "customers" for RadNet's operational and management capabilities. Key strategic partners and "customer" health systems include:

• MemorialCare Health System (Private Company)
• Hackensack Meridian Health (Private Company)
• CommonSpirit Health (Private Company, formed from the merger of Dignity Health and Catholic Health Initiatives, both of which were RadNet partners)
• Scripps Health (Private Company)
• University of Maryland Medical System (Private Company)

Most of RadNet's major health system partners are private entities and therefore do not have public company symbols.

Howard G. Berger, M.D. President and Chief Executive Officer

Dr. Berger co-founded RadNet in 1980 and has served as President and Chief Executive Officer of RadNet and its predecessor entities since 1987. He has over 25 years of experience in developing and managing successful healthcare businesses. Dr. Berger began his medical career at the University of Illinois Medical School, following his graduation from Western Reserve University. He is Board Certified in Nuclear Medicine and received training in an Internal Medicine residency, as well as a masters program in medical physics within the University of California system.

Mark D. Stolper Executive Vice President and Chief Financial Officer

Mr. Stolper has served as RadNet's Executive Vice President and Chief Financial Officer since 2004, having previously been an independent member of the company's Board of Directors. He is responsible for all aspects of RadNet's financial functions. Before joining RadNet, Mr. Stolper gained diverse experience in investment banking, private equity, venture capital investing, and operations. He began his career in the corporate finance group at Dillon, Read and Co., Inc., where he executed mergers and acquisitions, public and private financings, and private equity investments with Saratoga Partners LLP. He also worked for Archon Capital Partners, focusing on private equity investments in media and entertainment companies, and was a co-founder of Broadstream Capital Partners, an investment banking firm.

Norman R. Hames President and Chief Operating Officer for Western Operations

Mr. Hames oversees all aspects of facility operations for RadNet's Western Operations, bringing 20 years of industry experience. Before joining RadNet in April 1996, Mr. Hames was the President and CEO of his own company, Diagnostic Imaging Services, Inc. (DIS), which owned and operated 14 multi-modality imaging centers across Southern California. His initial experience in operating imaging centers was with American Medical International (AMI), where he was responsible for the development of their single and multi-modality imaging centers.

Kees Wesdorp President and Chief Executive Officer of RadNet's Digital Health division

Mr. Wesdorp is President and Chief Executive Officer of RadNet's Digital Health division. In 2023 and 2024, he served as a Managing Director at Hellman & Friedman, a private equity firm, where he focused on driving transformation at portfolio companies in Europe.

Michael Murdock Executive Vice President, Mergers and Acquisitions

Mr. Murdock joined RadNet in November 2006, following RadNet's acquisition of Radiologix. Prior to this, he served as Senior Vice President and Chief Financial Officer of Radiologix since January 2005.

There are two clear emerging threats for RadNet:

1. Accelerated advancements in artificial intelligence (AI) for diagnostic interpretation: While RadNet will likely integrate AI tools into its operations, the rapid development and increasing sophistication of AI algorithms pose a significant threat. AI has the potential to automate significant portions of image analysis, potentially reducing the reliance on human radiologists for initial reads, flagging anomalies, and even generating preliminary reports. This could lead to a commoditization of interpretive services, pressure on reimbursement rates for radiology reads, and a fundamental shift in the cost structure and staffing needs for imaging centers. The long-term implication could be a diminished competitive advantage based on the human expertise of radiologists, which is a core component of RadNet's service offering.

2. Disruptive non-imaging and point-of-care diagnostic technologies: The emergence of highly effective, less invasive, and more accessible diagnostic tools threatens to reduce the demand for traditional advanced imaging services. This includes sophisticated blood tests (e.g., liquid biopsies for cancer detection, multi-cancer early detection tests), highly portable and lower-cost imaging devices (e.g., handheld ultrasound, miniaturized MRI/CT units that can be used in primary care settings), and advanced biosensors. If these technologies prove to be sufficiently accurate and cost-effective, they could significantly reduce the volume of referrals for RadNet's core MRI, CT, and PET/CT scans by providing diagnostic information earlier, cheaper, or without the need for a specialized imaging center visit.

RadNet (symbol: RDNT) operates in two primary markets: outpatient diagnostic imaging services and artificial intelligence (AI) solutions for medical imaging.

Outpatient Diagnostic Imaging Services

The addressable market for RadNet's outpatient diagnostic imaging services is primarily the U.S. market. The U.S. imaging services market was valued at approximately USD 150.2 billion in 2024 and is projected to reach USD 192.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.30%. Other estimates place the U.S. diagnostic imaging services market size at USD 140.21 billion in 2024, with a projection to reach USD 239.74 billion by 2032, exhibiting a CAGR of 7.0%. Another source indicates the U.S. imaging services market size was USD 144.10 billion in 2023 and is projected to hit around USD 218.70 billion by 2033, with a CAGR of 4.26%. RadNet is the largest operator of freestanding, fixed-site diagnostic imaging centers in the United States, based on the number of locations and annual imaging revenue, operating over 400 centers across several states.

Artificial Intelligence (AI) Solutions for Medical Imaging

RadNet also provides radiology information technology and AI solutions through its DeepHealth brand. The global AI in medical imaging market size was estimated at USD 1.70 billion in 2024 and is expected to reach USD 16.88 billion by 2034, growing at a CAGR of 25.8%. Specifically for the U.S. market, the AI in medical imaging market size was estimated at USD 524.42 million in 2024 and is expected to expand at a CAGR of 33.24% from 2025 to 2030. North America, which includes the U.S., dominated the global AI in medical imaging market in 2024, holding a revenue share of 43.04%. The North America AI in Radiology Market alone was valued at USD 0.825 billion in 2024 and is projected to grow to USD 6.15 billion by 2035.

RadNet (RDNT) is expected to experience future revenue growth over the next 2-3 years driven by several key factors:

1. Growth in Advanced Imaging Volumes: The company anticipates continued robust growth in advanced imaging procedures such as MRI, CT, and PET/CT scans. This growth is driven by increased procedural volumes, including specific applications like PSMA (prostate) and amyloid brain studies, and a strategic shift in business mix towards these higher-margin services.
2. Expansion of Digital Health Segment and AI Solutions: RadNet's Digital Health segment, encompassing AI-related revenue, DeepHealth OS, TechLive, and strategic acquisitions like iCAD, is a significant driver of revenue growth. This expansion includes both the adoption of these solutions within RadNet's own imaging centers and increased external sales of its workflow software solutions.
3. New Imaging Center Openings and Capacity Enhancement: The company is focused on organic growth through the opening of new "de novo" imaging centers and enhancing capacity at its existing facilities to meet high patient demand.
4. Strategic Acquisitions: RadNet plans to continue pursuing attractive strategic acquisitions, including both imaging centers and digital health targets. This inorganic growth strategy, which has included "tuck-in" deals, is expected to further bolster its market position and service offerings.
5. Increased Reimbursement Rates: The company anticipates a positive impact from increased reimbursement rates from commercial and capitated payers. Furthermore, RadNet expects a net benefit from Medicare reimbursement in 2026, which breaks a trend of annual cuts.

Share Issuance

• In March 2024, RadNet completed a public offering of 4,550,000 shares of common stock, generating gross proceeds of approximately $200 million, with the intent to use the net proceeds for general corporate purposes and future acquisitions.
• The number of common shares issued and outstanding increased from 57,723,125 at December 31, 2022, to 67,956,318 at December 31, 2023, reflecting a substantial issuance of shares during 2023.
• On April 30, 2023, RadNet issued 144,227 shares of common stock to settle a $4.0 million holdback related to indemnification claims from an acquisition.

Outbound Investments

• RadNet has actively pursued acquisitions, spending over $54 million on various acquisitions in 2024 to expand its imaging center network in California and new markets like Houston, Texas.
• A significant strategic focus has been on artificial intelligence (AI) companies, highlighted by the acquisition of DeepHealth in 2020 for over $40 million, and later Dutch AI firms Quantib and Aidence in 2022 for a combined total of nearly $100 million.
• Continuing this trend in 2025, the company completed the acquisition of iCAD, Inc. in July, aiming to enhance its AI-powered breast health solutions, and acquired Alpha RT's assets in November to expand its remote imaging capabilities.

Capital Expenditures

• Capital expenditures for RadNet reached $153.0 million in 2023, with a focus on expanding capacity, developing de novo facilities, engaging in hospital joint ventures, and investing in information technology solutions.
• For 2024, the company's capital expenditures guidance was increased to $145 million - $155 million, primarily driven by continued spending on de novo center openings and significant infrastructure investments within its Digital Health segment.
• In 2022, capital expenditures amounted to $105.7 million, following $98.8 million in 2021, which included an opportunistic $26.0 million purchase of equipment that was previously under operating leases.